Most Read Articles
21 Jun 2016
Sofosbuvir-based regimens showed good cost-effectiveness in a majority of patients suffering from chronic hepatitis C, as observed in a systematic review of fourteen studies conducted in seven different countries.
14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).
Yesterday
Treatment with water-free cyclosporine formulation at either 0.1% or 0.05% concentration is tolerable and provides effective relief of the signs of dry eye disease, according to data from a phase II study.
4 days ago
New drug applications approved by US FDA as of 01 - 15 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date. 

Empagliflozin trims excess weight in overweight, obese women with PCOS

03 Apr 2019

The sodium‐glucose‐cotransporter‐2 (SGLT2) inhibitor empagliflozin yields beneficial effects on weight anthropometric parameters and body composition—including weight, body mass index (BMI), waist and hip circumference, and total body fat—that are greater than those achieved with metformin in overweight and obese women with polycystic ovary syndrome (PCOS), a study has shown.

The study randomized 39 women to receive either empagliflozin 25 mg (n=19; mean age, 26.0 years; mean BMI, 37.1 kg/m2) or metformin 1,500 mg (n=20; mean age, 31.5 years; mean BMI, 38.7 kg/m2) daily for 12 weeks. Outcomes evaluated were changes in anthropometric and body composition, hormonal and metabolic parameters.

By the end of treatment at week 12, empagliflozin produced superior improvements in some of the outcomes compared with metformin: weight (–1.4 percent vs 1.2 percent; p=0.006), BMI (–1.4 percent vs 1.1 percent; p=0.006), waist circumference (–1.6 percent vs 0.2 percent; p=0.029) and hip circumference (–2.0 percent vs 1.1 percent; p=0.001), basal metabolic rate (–1.8 percent vs 0.1 percent; p=0.024) and fat mass (–0.7 percent vs 3.2 percent; p=0.023).

However, there were no significant changes in hormonal or metabolic parameters observed in both treatment groups.

In terms of safety, no adverse events or serious adverse events occurred in the metformin group. On the other hand, two patients on empagliflozin reported headache and dizziness or mild rash, which were unrelated to the study drug.

Despite the encouraging data for empagliflozin, more placebo-controlled and comparative treatment trials of longer-term duration are needed to provide further insights into its effects on PCOS-related outcomes in women with different PCOS phenotypes and related complications (eg, diabetes) before this particular SGLT2 inhibitor gains a therapeutic place in PCOS, researchers said.

Lifestyle interventions involving diet, exercise and behavioural modifications should still be considered the first line of treatment for overweight or obese women with PCOS to reduce body weight, central obesity and insulin resistance, they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
21 Jun 2016
Sofosbuvir-based regimens showed good cost-effectiveness in a majority of patients suffering from chronic hepatitis C, as observed in a systematic review of fourteen studies conducted in seven different countries.
14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).
Yesterday
Treatment with water-free cyclosporine formulation at either 0.1% or 0.05% concentration is tolerable and provides effective relief of the signs of dry eye disease, according to data from a phase II study.
4 days ago
New drug applications approved by US FDA as of 01 - 15 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.